http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
-
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
-
Aeterna Zentaris (AEZS) Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
-
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
-
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
-
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Aeterna Zentaris (AEZS) Provides Corporate Update
-
Aeterna Zentaris Provides Corporate Update
-
Aeterna Zentaris Provides Corporate Update
-
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
-
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
-
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
-
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
-
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
-
Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market
-
Aeterna Zentaris (AEZS) announces $7M direct offering of common stock, warrants
-
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
-
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
-
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
-
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
-
AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY
-
AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY
-
Aeterna Zentaris (AEZS) Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
-
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
-
Aeterna Zentaris (AEZS) Prices 26.67M Unit Offering at $0.45/Unit
-
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING
-
AETERNA ZENTARIS ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING
-
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
-
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
-
Aeterna Zentaris (AEZS) Regains Compliance With Nasdaq Minimum Bid Price Requirement
-
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
-
Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
-
Aeterna Zentaris (AEZS) Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
-
Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
-
Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
-
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders
-
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders
-
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders
-
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders
-
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results
-
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results
-
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit
-
Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit

